Newsroom press releases

01/12/22 - 18:30

2023 Annual Calendar of Corporate Events (288 KB)

Other

09/11/22 - 7:04

DiaSorin Simplexa® cCMV Direct assay received U.S. FDA 510(K) clearance (134.99 KB)

Products Molecular

07/11/22 - 7:12

DiaSorin commercializes molecular reagent for monkeypox virus (149 KB)

Products Molecular

27/10/22 - 13:44

Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards (316.32 KB)

Financial Data

05/10/22 - 6:37

DiaSorin furthers its collaboration with BARDA for the LIAISON® NES (160.31 KB)

Products Molecular

14/09/22 - 0:29

DIASORIN SIMPLEXA™ COVID-19 TEST RECEIVED U.S. FDA 510(K) CLEARANCE (194.22 KB)

Products Molecular

03/08/22 - 12:26

Strong revenues growth in the First Half of 2022 - Full Year 2022 Guidance on both Revenues and Profitability revised upwards (316.69 KB)

Financial Data

14/07/22 - 20:00

DiaSorin receives FDA 510(k) clearance for its LIAISON® MeMed BV® test (160.88 KB)

Products Immunodiagnostic

07/06/22 - 18:06

Execution of the project for the redefinition of the corporate structure of DiaSorin (286.22 KB)

Other

20/05/22 - 7:08

DiaSorin CE Marks their ARIES® Flu A/B & RSV+SARS-CoV-2 Lowplex Assay (106.16 KB)

Products Molecular

09/05/22 - 7:02

DiaSorin and B·R·A·H·M·S, part of Thermo Fisher Scientific, partner to develop and commercialize the new LIAISON® B·R·A·H·M·S MR-proADM™ (173.49 KB)

Acquisition / Partnership

06/05/22 - 17:33

Update 2022 Annual Calendar of Corporate Events (285.68 KB)

Financial Disclosures

06/05/22 - 16:45

Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards (467.24 KB)

Financial Data

02/05/22 - 12:55

Publication of the summary report of the votes cast (280.95 KB)

Financial Disclosures

29/04/22 - 16:26

Shareholders' meeting 2022 (166.12 KB)

Other

22/04/22 - 12:37

New proposal for resolution related to the remuneration of the Board of Statutory Auditors (281.82 KB)

Financial Disclosures

13/04/22 - 16:43

DiaSorin: Publication of the updated proxy forms for voting through the Designated Representative (282.86 KB)

Financial Disclosures

08/04/22 - 19:13

Publication of the lists of candidates for the appointment of the Board of Directors, the Board of Statutory Auditors and relevant proposals for resolution (291.36 KB)

Financial Disclosures

08/04/22 - 9:53

Update annual calendar of corporate events 2022 (288.09 KB)

Financial Disclosures

05/04/22 - 9:51

Notice pursuant to art. 144-octies, paga 2 of Consob Regulation No. 11971/1999 (309.07 KB)

Other

04/04/22 - 18:12

Filing of the lists submitted by IP Investimenti e Partecipazioni S.r.l. (577.98 KB)

Other

16/03/22 - 17:39

DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021 (404.69 KB)

Financial Data

08/03/22 - 7:13

DiaSorin announces CE Marking of the new NxTAG® Gastrointestinal Molecular Multiplex Pathogen Panel (105.47 KB)

Products Molecular

13/01/22 - 7:24

DiaSorin releases an updated Simplexa™ SARS-CoV-2 Variants Direct molecular assay (RUO) for the detection of mutations associated with the Omicron variant (486.67 KB)

Products Molecular